WHO 2013 guidelines: what about the missing formulations?

WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500

Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013

Non-standard combinations: NRTI-sparing combinations

ARVs and bone health: the role of NRTIs in second-line therapy

No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors

HIV cure research: further capsules at IAS 2013

Partner-dependent immune differences may protect against HIV infection

Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes

5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur

Vertical transmission continues to decline in UK and Ireland

Decline in late preterm delivery with vaginal birth in Europe

High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+

Decreased growth in ART exposed uninfected infants in Botswana

Antiretrovirals, doses and formulations for children

International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, 4-8 June 2013, Toronto

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

One in five people with recent HIV infection in Spain have X4/R5 mixed tropic virus

Ending global use of d4T: UNITAID to tip market to safer alternatives

TRIPS extension for least developed countries

Community request Gilead to study and develop separate formulation of new tenofovir prodrug

Sad news regarding attempt to duplicate the cure achieved in Timothy Brown

ART reduces HIV reservoirs in elite controllers: implications for cure research

Bangkok Tenofovir Study: US CDC recommends oral PrEP for injecting drug users – based on 16 fewer infections over 5 years

CROI website: vital community and research resource vanishes

FDA guidance for industry HIV development and trials

TAG report: Immune system, HIV, and ageing

RITA! summer issue: HIV and cardiovascular disease

HTB supplement: 2013 pipeline report

Dedication: Spencer Cox

Seven ways to speed up the pipeline

Executive summary and research policy recommendations

The antiretroviral pipeline 2013

The paediatric antiretroviral pipeline

Retrofitting for purpose: treatment optimisation 2013

Preventive technologies, research toward a cure, and immune-based and gene therapies

Hepatitis C drug development catapults onward

Low- and middle-income countries defuse hepatitis C

The tuberculosis diagnostics pipeline

The tuberculosis treatment pipeline

The tuberculosis vaccine pipeline


Volume 14 Number 5/6 May/June 2013

14th International Workshop on Clinical Pharmacology, 22-24 April 2013, Amsterdam

Population pharmacokinetics of efavirenz to inform dosing in children three months of age and above

Bilirubin as a surrogate marker for atazanavir in children

Transplacental transfer of atazanavir and neonatal hyperbilirubinaemia

Tenofovir population pharmacokinetics in pregnancy

Effect of rifampicin on BMS-663068 in HIV negative volunteers

Coformulated darunavir/cobicistat: an alternative to separate ritonavir boosting

Continuous infusion of T-20 in multidrug resistant patient with intolerance of s.c. injections

20th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2013, Atlanta

Small increase in birth defects in the French Perinatal Cohort

Uptake and retention in Malawi’s Option B+ programme

Optimising ART initiation in pregnancy through linkage of services vs integration of ART into antenatal care

Cardiovascular disease and other non-AIDS defining events

Dramatic advances at CROI for HCV treatment: telaprevir, boceprevir, faldaprevir, sofosbuvir, ABT-450, ABT-267, ABT-333 and ledipasvir

Basic research highlights from CROI 2013

Probiotic/prebiotic supplement combination shows benefits in SIV-infected pigtailed macaques

Upcoming WHO ART guidelines (2013)

Fixed dose combination efavirenz/tenofovir/FTC for South Africa

Post navigation